SCHEMBL4136116

SCHEMBL4136116

[2H]C1CCCCN1N=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29390792 0.80 ALDH1A1 (0.32)
SCHEMBL105009 0.80 ALDH1A1 (0.32)
SCHEMBL605035 0.80
SCHEMBL1578024 0.80
SCHEMBL606668 0.76
SCHEMBL31423403 0.74
SCHEMBL11507080 0.70
SCHEMBL28712015 0.69 CA1 (0.35)
SCHEMBL31533292 0.65
SCHEMBL95309 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258902-A1 BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS CONCERT PHARMACEUTICALS INC. (US) 2009-10-15 US disclosed
US-7514068-B2 Biphenyl-pyrazolecarboxamide compounds CONCERT PHARMACEUTICALS INC. (US) 2009-04-07 US disclosed
US-20070276001-A1 Biphenyl-pyrazolecarboxamide compounds CONCERT PHARMACEUTICALS INC. (US) 2007-11-29 US disclosed
WO-2007033366-A2 BIPHENYL-PYRAZOLECARBOXAMIDE COMPOUNDS CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 WO disclosed
US-20070066657-A1 obesity, smoking cessation, and normalization of blood lipid composition; reduced rates of hepatic oxidative metabolism, ability to penetrate the blood-brain barrier; 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(trideuteromethyl)-1H-pyrazole-3-carboxylic acid; cannabinoid receptor antagonist CONCERT PHARMACEUTICALS INC. (US) 2007-03-22 US disclosed